Biopharmaceutical company.
MCM development & procurement process; S. 415, A bill to amend the Federal Food, Drug, and Cosmetic Act with respect to the scope of new chemical exclusivity.
HCR - Health Issues
2 - HOUSE OF REPRESENTATIVES 1 - SENATE
BAKER DONELSON BEARMAN CALDWELL & BERKOWITZ
901 K Street NW, Suite 900, Washington, DC, 20001, US
NICOLE CARELLI